Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday

Angelica Ballesteros

Wed, May 14, 2025, 5:50 AM 2 min read

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks.

Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than expected.

On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, bringing the annual inflation rate to 2.3 percent, versus the 2.4 percent in March. It was the lowest annual rate since February 2021.

Only the S&P 500 and the tech-heavy Nasdaq registered gains among all major indices, up by 0.72 percent and 1.61 percent, respectively. The Dow Jones, on the other hand, was down by 0.64 percent.

Beyond the main indices, 10 firms lagged in performance amid negative news, sparking sell-offs.

To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.

A team of scientists in white lab coats reviewing lab results in a research facility.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) saw its share price decline by 6.78 percent on Tuesday to finish at $33.26 each following President Donald Trump’s new executive order directing drugmakers to lower the prices of drugs.

BridgeBio Pharma, Inc. (NASDAQ:BBIO), a biotechnology company, dropped alongside its counterparts in the healthcare sector as investors feared that the new order would dent  the profits and margins of drugmakers and retailers.

In recent news, BridgeBio Pharma, Inc. (NASDAQ:BBIO) widened its net loss by 371 percent to $169.6 million in the first quarter of the year from $36 million in the same period a year earlier, while revenues fell by 45 percent to $116 million from $211 million year-on-year.  Of the total revenue, $36.7 million was attributed to Attruby.

Meanwhile, the company was gaining strong traction for its heart treatment, Attruby, having recorded 2,072 prescriptions written by 756 prescribers as of April 25.

Overall BBIO ranks 8th on our list of Tuesday's worst performers. While we acknowledge the potential of BBIO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BBIO but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.